Intervention
Candesartan
ClinicalTrials.gov intervention label
Explore related research
Search across original and mapped recordsSearch results distinguish clinical terminology from original registry names. Shared trial participation does not imply treatment or approval.
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov intervention label, found in 30 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
30 shownBariatric Surgery and Pharmacokinetics of CandesartanNCT03460327 · 2016-11-02
RECRUITINGEfficacy and Safety of a Quadruple Ultra-low-dose Treatment for HypertensionNCT03640312 · 2019-08-30
COMPLETEDStrain vs. Left Ventricular Ejection Fraction-based Cardiotoxicity Prevention in Breast CancerNCT04429633 · 2019-07-19
UNKNOWNAdiposity and Endothelin Receptor FunctionNCT03583866 · 2018-05-21
ACTIVE_NOT_RECRUITINGCandesartan's Effects on Alzheimer's Disease And Related BiomarkersNCT02646982 · 2016-06-30
COMPLETEDCAndesartan vs LIsinopril Effects on the BRainNCT01984164 · 2014-08-20
COMPLETEDGRK4 Polymorphisms Blood Pressure Response to CandesartanNCT01629225 · 2013-07-01
UNKNOWNEffects of Cerebral Hypoperfusion and Its Reversal on Late-Life DepressionNCT01794455 · 2013-05-01
TERMINATEDRAS Quantification in Patients With Aliskiren or CandesartanNCT01827202 · 2012-12-01
COMPLETEDCR Aim #2 - AT1 Receptor Blockade & ACE Inhibition Effect on Humoral FunctionNCT01678794 · 2012-02-01
COMPLETEDPrevention of Cardiac Dysfunction During Adjuvant Breast Cancer TherapyNCT01434134 · 2011-09-01
COMPLETEDChanges After Angiotensin Converting Enzyme (ACE) Inhibitor Replacement by Angiotensin II Receptor Type I (AT1) BlockerNCT01444833 · 2008-10-01
UNKNOWNImidapril and Candesartan on Fibrinolysis and Insulin-Sensitivity in Patients With Mild to Moderate HypertensionNCT00644475 · 2008-03-01
UNKNOWNA Randomized, Double-Blind, Active Control Trial Comparing Effects of Telmisartan, Candesartan and Amlodipine, Alone or Plus Metformin, on Non-Diabetic, Obese Hypertensive PatientsNCT00538486 · 2008-02-01
COMPLETEDObservational Usage and Efficacy Study of Candesartan in Heart Failure Treatment in FranceNCT00679640 · 2008-01-01
COMPLETEDEfficacy of Candesartan on Symptomatic Heart Failure in Treating Diabetic and Hypertensive Patients.NCT00775840 · 2008-01-01
COMPLETEDCCB Safety Study in Treatment of Hypertension of ADPKDNCT00541853 · 2007-12-01
UNKNOWNEvaluation of Heart Failure Treatment Guided by N-terminal Pro B-type Natriuretic Peptide (NTproBNP) vs Clinical Symptoms and Signs AloneNCT00391846 · 2006-10-01
COMPLETEDClinical Trial to Assess the Effects of Candesartan on the Carbohydrate Metabolism of Obese SubjectsNCT00319202 · 2006-06-01
TERMINATEDCandesartan Effectiveness Study in Pro-B Type Natriuretic Peptides (BNP)NCT00348686 · 2006-06-01
COMPLETEDEffectiveness of Candesartan and Telmisartan on Morning Hypertension in Japanese Obese PatientsNCT00288717 · 2006-02-01
UNKNOWNCandesartan for Prevention of Cardiovascular Events After Cypher or Taxus Coronary Stenting (4C) TrialNCT00139386 · 2005-10-01
COMPLETEDDouble-Blind Randomized Cross-Over Trial Comparing Metabolic Effects of Candesartan, Hydrochlorothiazide and PlaceboNCT00282178 · 2005-04-01
COMPLETEDAngiotensin II Antagonism of TGF-Beta 1NCT00320970 · 2002-08-01
COMPLETEDDanish Hypertension Prevention Project - DHYPPNCT00150631 · 2000-11-01
UNKNOWNDiabetes Type 1, Treatment Study Atacand/Placebo After Kidney BiopsyNCT00328302 · 2000-09-01
UNKNOWNCandesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Added)NCT00634309 · 1999-06-01
COMPLETEDCandesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Preserved)NCT00634712 · 1999-06-01
COMPLETEDCandesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Alternative)NCT00634400 · 1999-03-01
COMPLETEDGenetic Epidemiology of Responses to AntihypertensivesNCT00005520 · 1997-02-01
COMPLETEDCommon conditions
Hypertension14Heart Failure4Congestive Heart Failure3Obesity3Breast Cancer2Essential Hypertension2Mild Cognitive Impairment2Adjuvant1Cardiorenal Syndrome (CRS)1Cardiotoxicity1Cardiovascular Diseases1Chronic Kidney Disease1Cohort Study1Coronary Artery Disease1Depression1Diabetes, Type I1Diabetic Nephropathy1Glucose Intolerance1Heart Diseases1Kidney, Polycystic, Autosomal Dominant1Left Ventricular Hypertrophy1Obesity, Morbid1Prevention1Proteinuria1Trastuzumab1
Mapped diseases appearing in these trials
Shared study participation does not establish that this intervention treats a disease.
Leading sponsors
AstraZeneca
6
Emory University
2
Mayo Clinic
2
Third Military Medical University
2
Augusta University
1
Fundación Cardiovascular de Colombia
1
Karin Skov
1
Karolinska University Hospital
1
Kumamoto University
1
Kyorin University
1
Medical University of Vienna
1
Norwegian University of Science and Technology
1
Providence Health & Services
1
Saitama Medical University
1
Samsung Medical Center
1
Trial status mix
COMPLETED18
UNKNOWN8
TERMINATED2
ACTIVE_NOT_RECRUITING1
RECRUITING1
Phase mix
PHASE410
PHASE26
PHASE36
NA4
EARLY_PHASE11
PHASE11
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.